3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`PRO OPEN HOUSE ends in 12d 11h 19m 35s
`
`Try PRO now for Free >>
`
`Johnson & Johnson's Management Discusses Q3 2013 Results -
`Earnings Call Transcript
`
`Oct.15.13 | About: Johnson & (JNJ)
`
`Johnson & Johnson (NYSE:JNJ)
`
`Q3 2013 Earnings Call
`
`October 15, 2013, 8:30 am ET
`
`Executives
`
`Louise Mehrotra - Vice President of Investor Relations
`
`Dominic Caruso - Chief Financial Officer, Vice President - Finance
`
`Michel Orsinger - Worldwide Chairman of DePuy Synthes Companies
`
`Analysts
`
`Matthew Dodds - Citicorp
`
`Mike Weinstein - JPMorgan
`
`Kristen Stewart - Deutsche Bank
`
`Larry Biegelsen - Wells Fargo
`
`Tony Butler - Barclays Capital
`
`Bruce Nudell - Credit Suisse
`
`Jami Rubin - Goldman Sachs
`
`Rick Wise - Stifel
`
`Derrick Sung - Sanford Bernstein
`
`Danielle Antalffy - Leerink Swann
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`1/39
`
`JANSSEN EXHIBIT 2141
`Mylan v. Janssen IPR2016-01332
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`Glenn Novarro - RBC Capital Markets
`
`Bob Hopkins - Bank of America
`
`Operator
`
`Good morning, and welcome to the Johnson & Johnson third quarter 2013 earnings
`
`conference call. All participants will be able to listen-only until the question-and-answer
`
`session of the conference. This call is being recorded. If anyone has any objections you
`
`may disconnect at this time. (Operator Instructions).
`
`I would now like to turn the call over to Johnson & Johnson, you may begin.
`
`Louise Mehrotra
`
`Good morning, and welcome. I am Louise Mehrotra, Vice President of Investor Relations
`
`for Johnson & Johnson and it is my pleasure this morning to review our business results
`
`for the third quarter of 2013. Joining me on the call today are Dominic Caruso, Vice
`
`President, Finance and Chief Financial Officer and Michel Orsinger, Worldwide Chairman
`
`of DePuy Synthes Companies.
`
`A few logistics before we get into the details. This review is being made available to a
`
`broader audience via webcast accessible through the Investor Relations section of the
`
`Johnson & Johnson website. I will begin by briefly reviewing highlights of the third quarter
`
`for the corporation and highlights for our three business segments.
`
`Following my remarks, Michel will provide an update on our DePuy Synthes business and
`
`the progress made on our near-term priorities in successfully integrating Synthes. Please
`
`note the presentations that accompanies Michel's remarks is available on our website.
`
`Next Dominic will provide some additional commentary on the financial results and
`
`guidance for 2013. We will then open the call to your questions. We expect the call to last
`
`approximately 90 minutes. Included with the press release that was issued earlier this
`
`morning is a schedule of sales for key products and/or businesses to facilitate updating
`
`your models. These schedules are available on the Johnson & Johnson website as is the
`
`press release.
`
`Before I get into the results, let me remind you that some of the statements made during
`
`this review may be considered forward-looking statements. The 10-K for the fiscal year
`
`2012 identifies certain factors that could cause the company's actual results to differ
`
`materially from those projected in any forward-looking statements made today. The
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`2/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`company does not undertake to update any forward-looking statements as a result of new
`
`information or future events or developments. The 10-K is available through the company
`
`and online.
`
`During the review, non-GAAP financial measures are used to provide information pertinent
`
`to ongoing business performance. These non-GAAP financial measures should not be
`
`considered replacements for GAAP results. Tables reconciling these measures to the
`
`most comparable GAAP measures are available in the press release and on the Investor
`
`Relations section of the Johnson & Johnson website at investor.jnj.com.
`
`Now, I would like to review our results for the third quarter of 2013. If you would refer to
`
`your copy of the press release, let's begin with the schedule titled, supplementary sales
`
`data by geographic area.
`
`Worldwide sales to customers were $17.6 billion for the third quarter of 2013, up 3.1% as
`
`compared to the third quarter of 2012. On an operational basis, sales were up 4.7% and
`
`currency had a negative impact of 1.6%. In the U.S., sales were up 1.7%. In regions
`
`outside the U.S., our operational growth was 7.1%, while the effect of currency exchange
`
`rates negatively impacted our reported results by 2.9 points. Europe grew 8.4% on an
`
`operational basis while the western hemisphere, excluding the U.S., grew by 8%
`
`operationally. Asia-Pacific/Africa region grew 5.1% operationally. The success of new
`
`product launches made strong contributions to the results in all regions.
`
`If you now turn to the consolidated statements of earnings, net earnings were $3 billion
`
`consistent with the 2012 results. Earnings per share were $1.04 versus $1.05 a year ago.
`
`Please direct your attention to the box section of the schedule where we have provided
`
`earnings adjusted to exclude special items. As referenced in the accompanying table
`
`reconciling non-GAAP measures, 2013 third quarter net earnings were adjusted to
`
`exclude the after-tax special items of $937 million, primarily related to an increase in the
`
`accrual for litigation expenses, in-process research and development and integration costs
`
`associated with the acquisition of Synthes.
`
`Third quarter 2012, net earnings included after-tax special items of approximately $553
`
`million as shown in the reconciliation of non-GAAP financial measures, excluding these
`
`special items for both periods, net earnings for the current quarter were $3.9 billion and
`
`diluted earnings per share were $1.36, representing increases of 11.3% and 8.8%,
`
`respectively as compared to the same period in 2012.
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`3/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`I would now like to make some additional comments relative to the components leading to
`
`earnings before we move onto the segment highlights. For the third quarter of 2013, cost
`
`of goods sold at 30.4%, was down 240 basis points from the same period last year. In the
`
`third quarter of 2012, we recorded an inventory step up charge related to the Synthes
`
`acquisition. Excluding the inventory step up charge, which was treated as a special item,
`
`cost of goods sold decreased 150 basis points versus the same period last year. Positive
`
`mix, strong volume growth in our Pharmaceutical business and cost improvement
`
`initiatives across many of the businesses was partially offset by the impact of the medical
`
`device excise tax.
`
`Third quarter selling, marketing and administrative expenses, were 30.2% of sales, or 40
`
`basis points lower than our 2012 results due to cost containment initiatives across many of
`
`the businesses. Our investment in research and development as a percent of sales was
`
`11.6%, up 30 basis points due to increased spending in the Pharmaceuticals business.
`
`Interest expense, net of interest income of $87 million was down $33 million versus the
`
`third quarter of 2012, due to a lower average debt level.
`
`Other expense net of other income of $943 million in the third quarter of 2013, compared
`
`to other income net of other expense of $19 million in the same period last year. Excluding
`
`special items, other income net of other expense of $43 million was $132 million less than
`
`2012, due primarily to the impact of 2012 gains on divestitures. Excluding special items,
`
`the effective tax rate was 18.9% in the third quarter of 2013 compared to 22.2% in the
`
`same period last year. Dominic will provide commentary on taxes in his remarks.
`
`Turning now to business segment highlights, please refer to the supplementary sales
`
`schedule highlighting key products or businesses for the third quarter of 2013. I will begin
`
`with the consumer segment.
`
`Worldwide consumer segment sales for the third quarter of 2013 of $3.6 billion, increased
`
`0.8% as compared to the same period last year. On an operational basis, sales increased
`
`2%, while the impact of currency was negative 1.2%. U.S. sales were up 0.9%, while
`
`international sales grew 2.6% on an operational basis.
`
`Excluding the impact of divestitures net of acquisitions, operational growth was
`
`approximately 2.5%. Baby care products increased on an operational basis by 2.6% when
`
`compared to the third quarter of 2012, due primarily to the impact of the health care
`
`products acquired earlier this year.
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`4/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`Sales in the Oral Care business decreased 3% operationally. Excluding the impact of the
`
`divestiture of manual toothbrushes in North America, operational sales were essentially
`
`flat.
`
`For the third quarter of 2013, sales for OTC Pharmaceuticals increased 6.5% on an
`
`operational basis compared to the same period in 2012. U.S. sales were up 17.9%, driven
`
`by strong growth in analgesics and other key brands as we continue to make progress in
`
`returning a reliable supply of products to the marketplace.
`
`International sales were up 2% operationally. Our skin care business grew 2.7% on an
`
`operational basis in the third quarter of 2013. Strong results for AVEENO were partially
`
`offset by the impact of divestitures. Excluding divestitures, operational growth was
`
`approximately 4%. Women's health grew 2.5% on an operational basis due to growth in
`
`international women's sanitary protection products. Wound care other sales decreased
`
`6.9% on an operational basis impacted by competitive pressures as well as divestitures.
`
`That completes our review of the consumer segment and I will now review highlights for
`
`the pharmaceutical segment. Worldwide net sales for the third quarter of $7 billion
`
`increased 9.9% versus the same period last year. On an operational basis, sales
`
`increased 10.9% with a negative currency impact of one point. Sales in the U.S. increased
`
`7.9%, while sales outside the U.S. increased on an operational basis by 14%.
`
`Now reviewing sales for major therapeutic areas. Immunology products grew 13.4%
`
`operationally, with sales in the U.S. up 3% and sales outside the U.S. up 47.7%
`
`operationally. Earlier this year, the company made certain supply chain changes for
`
`REMICADE resulting in sales to distributors previously recorded as U.S. export sales now
`
`being recorded as international sales. Adjusting for this impact the U.S. immunology
`
`growth was approximately 8% and operational growth outside the U.S. was approximately
`
`28%.
`
`In the U.S., REMICADE excluding export sales was up 7.8%, SIMPONI was up 19.4%
`
`and STELARA are was up 23.9%. Results were driven by market growth across the major
`
`products complemented by increased market share for both STELARA and SIMPONI.
`
`With the strength of our portfolio, we continue to be the U.S. market leader in immunology.
`
`REMICADE outside the U.S., adjusted for the supply chain change just mentioned, was
`
`up approximately 15% operationally due to strong growth in Canada and the emerging
`
`markets. STELARA made significant contributions to growth outside the U.S. due to
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`5/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`market share gains and market growth across the major regions while SIMPONI's strong
`
`growth was due to increased shipments to our distribution partner, complemented by
`
`additional country launches and strong growth in other markets.
`
`Sales of infectious disease products increased 2.4% on an operational basis. INCIVO, a
`
`treatment for Hepatitis C, grew 5.3% on an operational basis, reflecting launches in
`
`additional countries partially offset by lower sales in Europe impacted by a combination of
`
`patient warehousing, patients enrollment in clinical trials and seasonality in treatment
`
`patterns impacting new patient starts in the summer months. Continued momentum in
`
`market share growth in the major markets for PREZISTA made notable contributions to
`
`the results. Results outside the U.S. were impacted by the timing of tender business.
`
`Strong growth for the combined sales of COMPLERA and EDURANT also contributed to
`
`the results.
`
`Neuroscience product sales declined 1.9% operationally with U.S. sales down 11.4%
`
`impacted by generic competition primarily for CONCERTA. The long-acting injectable
`
`antipsychotics, RISPERDAL CONSTA and INVEGA SUSTENA or XEPLION achieved
`
`operational growth of over 15% due to an increase in combined market share. Sales of
`
`oncology products increased 57% on an operational basis due to the strong results for
`
`ZYTIGA and VELCADE. ZYTIGA is approved to treat both chemo refractory and chemo
`
`naïve metastatic castration resistant prostate cancer.
`
`In the quarter, ZYTIGA achieved operational sales growth of over 70%, with U.S. sales
`
`growing 50% due to very strong market growth of nearly 25% and increased market share
`
`in the combined metastatic castrate resistant prostate cancer market. ZYTIGA has
`
`captured 33% of that market and is up approximately 2.5 points sequentially. ZYTIGA
`
`sales outside the U.S. nearly doubled on an operational basis versus third quarter of 2012
`
`and on a sequential basis, sales were up over 15%. Additional country rollouts and the
`
`expansion of the label to chemo naïve patients drove the strong results. ZYTIGA is
`
`approved in more than 80 countries.
`
`VELCADE is a treatment for multiple myeloma. Sales increased 26.3% on an operational
`
`basis. Strong performance in patient share in the frontline setting and the launch of the
`
`subcutaneous version continue to drive sales growth. Other oncology increased primarily
`
`due to DOXIL/CAELYX. Regarding DOXIL/CAELYX, ensuring a efficient supply for
`
`physicians and their patients remained our urgent priority. We have begun to encounter
`
`supply outages of DOXIL in the U.S. due to issues at our third-party manufacturer. We
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`6/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`continue to take the steps needed for the long-term transition to suppliers, which we are
`
`accelerating wherever possible. The FDA has approved the generic doxorubicin
`
`hydrochloride liposome injection, which is currently available for patients.
`
`In Europe, the Committee for Medicinal Products for Human Use, or CHMP has approved
`
`manufacturing at CAELYX from an alternate supplier. We anticipate receiving CAELYX
`
`from this manufacturer by the end of the year.
`
`Other pharmaceutical products increased 5.9% on an operational basis with strong results
`
`for XARELTO and INVOKANA partially offset by lower sales for EPREX and PARIET,
`
`primarily related to generic competition.
`
`XARELTO more than tripled compared with the same quarter last year and grew nearly
`
`30% on a sequential basis, reaching nearly 40% of the new two brand scripts in cardiology
`
`in September, surpassing warfarin by over eight points and widening the lead by three
`
`points versus the last quarter.
`
`Total prescription exit share in the broader anticoagulant market grew approximately 1.5
`
`points on a sequential basis to nearly 10%.
`
`In the U.S., INVOKANA achieved 17% new to brand share with endocrinologists within the
`
`defined market of type-2 diabetes excluding insulin and metformin. At 17%, INVOKANA is
`
`the number one branded non-insulin product NBRx in that market. In addition to the
`
`number of approvals and filings that Dominic will highlight in his remarks, during the
`
`quarter, ibrutinib was granted priority review by the FDA for the use in the treatment of
`
`previously treated patients with chronic lymphocytic leukemia or CLL, and small
`
`lymphocytic lymphoma or SLL and for its use in the treatment of previously treated
`
`patients with mantle cell lymphoma, or MCL. In late February, PDUFA date has been
`
`assigned.
`
`We announced the simultaneous submissions of a biologic license application to FDA and
`
`a marketing authorization application to the European Medicines Agency or EMA for
`
`siltuximab, an experimental product for the treatment of patients with multicentric
`
`Castleman disease. The resubmission to the FDA complete response for the use of
`
`XARELTO to reduce the risk of secondary cardiovascular events and [Centrum] in patients
`
`with acute coronary syndrome was filed with a PDUFA date of mid-February, next year.
`
`In October, a marketing authorization application was submitted to the EMA, seeking
`
`approval for a once-daily single tablet fixed dose antiretroviral combination product
`
`containing darunavir, a protease inhibitor developed by Johnson with cobicistat, a
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`7/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`pharmacokinetic enhancer developed by Gilead Sciences for use in combination with
`
`other HIV-1 medicines.
`
`That completes the review of the Pharmaceutical segment. I will now review the Medical
`
`Devices and Diagnostics segment results. Worldwide medical devices and diagnostic
`
`segment sales of $6.9 billion, declined 2% versus for the same period last year. On an
`
`operational basis, sales increased 0.3% with a negative currency impact of 2.3 points.
`
`Sales in the U.S. declined 4.2%, while sales outside the U.S. increased on an operational
`
`basis by 4.2%. Adjusted for divestitures and exits from certain businesses, underlying
`
`growth was approximately 1% reflecting continued market and pricing pressure.
`
`I will provide more commentary on these factors in the franchise reviews. Starting with
`
`cardiovascular care, sales were up 4.2% operationally with U.S. up 0.5%, and sales
`
`outside the U.S. up 6.6% operationally, driven by Biosense Webster, our Electrophysiology
`
`business, with worldwide operational growth of over 11% in the quarter. The success of a
`
`number of capital launches made strong contributions to the results.
`
`Diabetes care sales declined 11.3% on an operational basis in the third quarter of 2013
`
`with the U.S. business down 27.7% due to the impact of lower price primarily related to
`
`competitive bidding. The business outside the U.S. was up 6.5% operationally with strong
`
`sales in the emerging markets partially offset by lower sales in some of the developed
`
`markets. The success of the launch of Animas Vibe in certain international countries has
`
`contributed to growth in the quarter.
`
`The diagnostics business declined 8% on an operational basis. Excluding the impact of
`
`the divestiture of the Virco's business, operational sales were down approximately 2.5%
`
`due to the exit from certain donor screening contracts and lower capital placements.
`
`Infection prevention decreased 0.5% on an operational basis with sales in the U.S. down
`
`7.1% due to the soft capital equipment sales reflecting a lower level of trade-ins. Outside
`
`the U.S., operational growth of 4.3% was driven by both consumables and capital item
`
`sales.
`
`Orthopedic sales were up 1.1% on an operational basis when compared to the same
`
`period in 2012 with the U.S. down 0.8% and sales outside the U.S. up 3.4%.
`
`Operationally, hips were up 6% worldwide driven by 7% growth in U.S. due to strong
`
`results on primary stent platforms sales partially offset by continued pricing pressure. Hips
`
`outside the U.S. were up 4% on the operational basis driven mainly by heads and
`
`acetabular products. Knees worldwide increased 3% on an operational basis with similar
`
`results both in and outside the U.S. Growth in the U.S. was due to the successful launch
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`8/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`of ATTUNE Fixed Bearing Knee as well as strong sales of Revision platforms partially
`
`offset by lower sales of rotating platforms and pricing pressure. The launch of ATTUNE
`
`drove the results outside the U.S.
`
`Trauma was up 1% on an operational basis with the U.S. flat and outside the U.S., up 2%
`
`operationally. Low cost competition impacted to the results in the U.S. while the timing of
`
`tender business negatively impacted the results outside the U.S. Worldwide spine was
`
`down 2% on an operational basis with the U.S. down approximately 10% impacted by
`
`pricing pressures, the continued softness in the market as well as the disruption in the
`
`commercial sales organization as we integrate the businesses. Outside the U.S., sales
`
`were up approximately 9% operationally, with strong growth in Latin America and Asia-
`
`Pacific.
`
`Specialty surgery operational growth was 6.7% in the third quarter of 2013. U.S. sales
`
`were up 4.2% and sales outside the U.S. up 9.2% on an operational basis. Strong sales of
`
`biosurgical products and international sales of energy products were the major
`
`contributors to growth, complemented by sales growth from new products for both
`
`MENTOR and ACCLARENT. These gains were partially offset by lower sales of
`
`HARMONIC products in the U.S. due to competitive pressures.
`
`Surgical care worldwide sales were up 1.4% on an operational basis, with U.S. down 2.5%
`
`and sales outside the U.S. up 3.9% operationally. U.S. sales were impacted by lower
`
`sales of women's health and urology products. Outside the U.S., future sales and strong
`
`demand for endocutter products with the ECHELON FLEX powered ENDOPATH Stapler
`
`were the important drivers of growth.
`
`Rounding up the review of the medical devices and diagnostic segment. Our vision care
`
`business achieved operational sales growth of 3.9% in the third quarter with U.S. up 1.9%
`
`and sales outside the U.S. up 4.9% operationally. Growth was driven by daily lenses and
`
`ASTIGMATISM lenses. That completes highlights for the medical devices and diagnostics
`
`segment and concludes the segment highlights for Johnson & Johnson's third quarter of
`
`2013.
`
`It is now my pleasure to turn the call over to Michel Orsinger. Michel?
`
`Michel Orsinger
`
`Thank you, Louise, and good morning, everyone. I look forward to providing you with an
`
`update on the integration of the DePuy and Synthes, the value we are seeing in the
`
`combination of these two companies and our strategy for leading and shaping the
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`9/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`industry. Having now worked with Johnson & Johnson prior to the Synthes acquisition,
`
`and now as a J&J leader, I have had ample opportunity to get to know the enterprise and
`
`discover its richness, breadth, resources and capabilities.
`
`I am very impressed by the values expressed in our credo and the ability of a large global
`
`organization to nourish and live by such values in an increasingly complex world. I now
`
`have a lot of respect for the people in Johnson & Johnson.
`
`Before I start my presentation, I would like to give my perspective on the DePuy Synthes
`
`third quarter results that Louise presented. While I am not entirely satisfied with our
`
`results, we have had some important wins. Joint reconstruction, especially in the U.S., is
`
`performing very well and we believe we grew market share in hips. Furthermore we
`
`generated double-digit growth in emerging markets with the best results coming from
`
`China, Russia and Brazil.
`
`Our performance in trauma and U.S. spine was lower than expected. Trauma results were
`
`due mostly to a biannual tender that did not repeat this year and pressure from lower price
`
`competition which we are managing by leveraging sales force coverage, segmenting the
`
`market and introducing new product configurations. U.S. spine results were due to
`
`integration disruptions which we are addressing.
`
`Overall, we are pleased to maintain our strong market leadership positions. I am very
`
`confident about the future. DePuy and Synthes, two of the most successful and respected
`
`companies in orthopedics and neuro, joined together at the right time to actively
`
`participate in and shape the changing healthcare environment. I am convinced that we are
`
`all well positioned to expand our leadership in the industry and I am excited by the
`
`opportunities in front of us.
`
`As a combined organization, we are better suited to optimize our offerings. For patients
`
`and surgeons, there is the potential for exciting medical innovations that leverage the
`
`product development capabilities from both organizations as well as from the larger J&J
`
`enterprise. For providers, our scaled and unparalleled product portfolio which spans many
`
`platforms opens new possibilities to consolidate suppliers. In emerging markets, the same
`
`benefit will enable us to continue accelerating growth. In addition, our larger experienced
`
`sales force, leadership and professional education, and collaboration with the AO, and the
`
`values driven, combined talent from both organizations offer competitive differentiation in
`
`the industry.
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`10/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`DePuy Synthes participates in a market that has very strong fundamentals. At $44 billion
`
`the market is large and diverse. There is plenty of opportunity to address unmet
`
`orthopedic and neuro needs. We believe that as the global population ages, demand for
`
`the types of products we offer will increase and many emerging markets are investing in
`
`the healthcare systems to provide more and better care for their citizens.
`
`As you look over our planning horizon, emerging market growth is projected to increase
`
`roughly four times the rate of developed markets. As healthcare systems around the world
`
`face the reality of cost containment and provide us participate more in decision making
`
`with clinicians, DePuy Synthes as part of J&J is primed to offer new value-added solutions
`
`and help transform healthcare delivery.
`
`Against the backdrop of these market dynamics, we are expecting the worldwide ortho
`
`and neuro market to grow between 2% and 4% compounded annually by 2017. Our first
`
`year at DePuy Synthes has been exciting and rewarding. As you can imagine combining
`
`two organizations of this size and complexity is a significant undertaking. Our employees
`
`are doing a great job and I am pleased to say the integration is on track.
`
`Our primary goal during the integration was to minimize customer disruption. Based on
`
`feedback from customers, we believe we have achieved this in all, but one platform. As
`
`we combine two different sales forces with two different sales models in U.S. spine, we
`
`have experienced some disruptions in that business and we continue to take corrective
`
`measures.
`
`In other parts of the business, I am particularly encouraged to see synergies being
`
`realized by cross-selling initiatives we envisioned from the onset, as well as revenue and
`
`cost synergies. Initially having very much focused on commercial integration, we are now
`
`spending more time on internal systems and processes, including IT, HR, supply chain
`
`and quality. This work remains a priority as the successful integration is one of the
`
`foundational elements of our future.
`
`We have combined terrific talent from both organizations and supplemented our team with
`
`new capabilities to help address the changes in our markets. We achieved a high
`
`retention rate of our global DePuy Synthes staff during integration and we are engaging in
`
`a new innovation agenda.
`
`Our strategy is focused on four growth drivers. We have continued to transform our
`
`business and drive growth through continuous innovation, focus on emerging markets,
`
`excellent execution and cultivation of talent and an engaged organization. For the rest of
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`11/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`today's discussion, I will focus on our approach to innovation and our emerging market
`
`strategy.
`
`In today's dynamic healthcare environment, our customers are looking for new solutions
`
`that improve clinical outcomes, increased patient satisfaction and do this at reduced cost,
`
`specifically to address patient satisfaction and to unmet patient needs, improving the
`
`instability some patients experience with existing knew replacements.
`
`ATTUNE also was developed to address provider interest in outcomes and efficiency of
`
`healthcare delivery. To-date, 27 publications document the science behind the design
`
`thereby addressing our stakeholders' need for evidence. The ATTUNE knee system
`
`launch is off to a very successful start with positive feedback from patients, surgeons and
`
`physical therapists. Following commercialization in North America, launches are underway
`
`in 13 European and Asia-Pacific countries.
`
`In addition to developing new products, we have started to complement our product
`
`offering with value-added programs and services. Let me describe one such program we
`
`are piloting, DePuy partnered with CAELYX [ph] and Janssen to create a program to help
`
`hospital reduce the length of stay for joint replacement patients while enhancing quality of
`
`care and patient satisfaction. The result is a patient care pathway program called
`
`Care4Today Orthopedic Solutions that integrates patient education, a change
`
`management program for hospitals and home recovery support. The first impressive
`
`results from the pilot show reduced patient length of stay and excellent patient and staff
`
`feedback.
`
`The third pillar of innovation is new business models. We are piloting many different cross-
`
`selling arrangements across DePuy Synthes and J&J that leverage our considerable
`
`product portfolio. For example, in the U.S., joint recon distributors are selling power tools
`
`and they are in community and they are rural community and rural hospitals selling
`
`trauma. Trauma is selling joint week on as sports medicine products in academic centers.
`
`Sports medicine is selling trauma products in community and rural hospitals and
`
`ambulatory research centers. Across Johnson & Johnson, Ethicon is selling and marketing
`
`CMS tissue metrics product as part of its hernia portfolio.
`
`We formed a strategic account management group that is leveraging our broader offerings
`
`to become one point of contact for all of our customers' orthopedic and neuro needs. As
`
`providers seek to reduce vendors, the team is steadily gaining traction in identifying and
`
`winning accounts that would benefit most from our comprehensive portfolio.
`
`http://seekingalpha.com/article/1746172-johnson-and-johnsons-management-discusses-q3-2013-results-earnings-call-transcript?part=single
`
`12/39
`
`

`

`3/7/2017
`
`Johnson & Johnson's Management Discusses Q3 2013 Results - Earnings Call Transcript | Seeking Alpha
`
`Taking collaboration one step further we are in active discussions with large institutions to
`
`jointly define value, based on their specific needs, set new standards and pilot entirely
`
`new approaches to delivering healthcare. The combination of the DePuy and Synthes and
`
`even the broader efforts across MD&D and J&J, place us in a very unique position to
`
`accomplish these goals.
`
`Now, I would like to move to another significant source of future growth, emerging